B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma

Cancer Science

Volumn 100, Issue 11, 2009, Pages 2093-2100

  Yamamoto, Ryo ^a   Nishikori, Momoko ^a   Tashima, Masaharu ^a   Sakai, Tomomi ^a   Ichinohe, Tatsuo ^a   Takaori Kondo, Akifumi ^a   Ohmori, Katsuyuki ^b   Uchiyama, Takashi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B7 ANTIGEN; B7 H1 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NUCLEOPHOSMIN; PHORBOL 12 ACETATE 13 MYRISTATE; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HODGKIN DISEASE; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION;

ANTIGENS, CD; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HODGKIN DISEASE; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROTEIN-TYROSINE KINASES; STAT3 TRANSCRIPTION FACTOR;

EID: 71049126550     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01302.x     Document Type: Article

References (36)

1. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004, 4:336-47.
2. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005, 23:515-48.
3. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008, 8:467-77.
4. Thompson RH, Gillett MD, Cheville JC. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004, 101:17174-9.
5. Ohigashi Y, Sho M, Yamada Y. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005, 11:2947-53.
6. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002, 99:12293-7.
7. Dong H, Strome SE, Salomao DR. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002, 8:793-800.
8. Yamamoto R, Nishikori M, Kitawaki T. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008, 111:3220-4.
9. Fischer P, Nacheva E, Mason DY. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood 1988, 72:234-40.
10. Mason DY, Bastard C, Rimokh R. CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35. Br J Haematol 1990, 74:161-8.
11. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 1994, 9:1567-74.
12. Morris SW, Kirstein MN, Valentine MB. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994, 263:1281-4.
13. Bai RY, Dieter P, Peschel C, Morris SW, Duyster J. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol 1998, 18:6951-61.
14. Zamo A, Chiarle R, Piva R. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002, 21:1038-47.
15. Chiarle R, Simmons WJ, Cai H. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005, 11:623-9.
16. Marzec M, Zhang Q, Goradia A. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A 2008, 105:20852-7.
17. Nishikori M, Maesako Y, Ueda C, Kurata M, Uchiyama T, Ohno H. High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease. Blood 2003, 101:2789-96.
18. Begum NA, Kinoshita K, Kakazu N. Uracil DNA glycosylase activity is dispensable for immunoglobulin class switch. Science 2004, 305:1160-3.
19. Watanabe M, Sasaki M, Itoh K. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. Cancer Res 2005, 65:7628-34.
20. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009, 9:15-27.
21. Lee SJ, Jang BC, Lee SW. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett 2006, 580:755-62.
22. Parsa AT, Waldron JS, Panner A. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007, 13:84-8.
23. Liu J, Hamrouni A, Wolowiec D. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007, 110:296-304.
24. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008, 8:11-23.
25. Amin HM, Medeiros LJ, Ma Y. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene 2003, 22:5399-407.
26. Marzec M, Kasprzycka M, Ptasznik A. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Lab Invest 2005, 85:1544-54.
27. Marzec M, Kasprzycka M, Liu X, Raghunath PN, Wlodarski P, Wasik MA. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. Oncogene 2007, 26:813-21.
28. Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 2000, 96:4319-27.
29. Rassidakis GZ, Feretzaki M, Atwell C. Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. Blood 2005, 105:827-9.
30. Kasprzycka M, Marzec M, Liu X, Zhang Q, Wasik MA. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc Natl Acad Sci U S A 2006, 103:9964-9.
31. Staber PB, Vesely P, Haq N. The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood 2007, 110:3374-83.
32. Pulford K, Falini B, Banham AH. Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood 2000, 96:1605-7.
33. Passoni L, Scardino A, Bertazzoli C. ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. Blood 2002, 99:2100-6.
34. Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 2003, 22:5108-21.
35. Kozako T, Yoshimitsu M, Fujiwara H. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia 2009, 23:375-82.
36. Younes A, Aggarwall BB. Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. Cancer 2003, 98:458-67.